首页 | 本学科首页   官方微博 | 高级检索  
检索        

脑脊液MGMT启动子甲基化在胶质瘤诊断中的应用
引用本文:王龙,黄彩菲,葛剑,陈治标,蔡强,刘宝辉,陈谦学.脑脊液MGMT启动子甲基化在胶质瘤诊断中的应用[J].肿瘤防治研究,2018,45(10):796-799.
作者姓名:王龙  黄彩菲  葛剑  陈治标  蔡强  刘宝辉  陈谦学
作者单位:430060 武汉,武汉大学人民医院神经外科
摘    要:目的 比较胶质瘤患者脑脊液与外周血中MGMT(O6-甲基鸟嘌呤-DNA-甲基转移酶)启动子甲基化在胶质瘤初期诊断中的敏感度和特异性。方法 收集283例胶质瘤患者肿瘤组织及其对应的术前外周血和脑脊液,10例颅脑外伤患者挫伤的脑组织及其对应的术前外周血、脑脊液。MGMT启动子甲基化状态通过甲基化特异性PCR(methylation-specific PCR, MSP)确定,比较脑肿瘤组织,外周血和脑脊液中MGMT启动子甲基化率。结果 不同级别胶质瘤组织MGMT启动子甲基化阳性率分别为68.13%(WHO Ⅱ)、65.69% (WHO Ⅲ)以及 67.78%(WHO Ⅳ),三者之间差异无统计学意义(P>0.05)。胶质瘤瘤体组织、对应的外周血和脑脊液启动子甲基化率为分别为67.14%、44.87%和66.08%,阴性对照组中检测结果均为0。MGMT启动子甲基化阳性瘤体组织,对应的脑脊液中MGMT启动子甲基化敏感度为79.66%(141/177),较对应的外周血58.82%(110/187)高(P<0.05)。结论 术前患者肿瘤组织、脑脊液和外周血中MGMT启动子甲基化率与肿瘤级别无关。与外周血相比,脑脊液中的 MGMT 启动子甲基化特异性和敏感度更高。

关 键 词:体液DNA  甲基化  胶质瘤早期诊断  MGMT基因启动子  脑脊液  
收稿时间:2018-01-26

Application of MGMT Promoter Methylation of Cerebrospinal Fluid in Diagnosis of Glioma
WANG Long,HUANG Caifei,GE Jian,CHEN Zhibiao,CAI Qiang,LIU Baohui,CHEN Qianxue.Application of MGMT Promoter Methylation of Cerebrospinal Fluid in Diagnosis of Glioma[J].Cancer Research on Prevention and Treatment,2018,45(10):796-799.
Authors:WANG Long  HUANG Caifei  GE Jian  CHEN Zhibiao  CAI Qiang  LIU Baohui  CHEN Qianxue
Institution:Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, China
Abstract:Objective To compare the sensitivity and specificity of O6-methylguanine-DNA methyltransferase(MGMT) promoter methylation between peripheral blood and cerebrospinal fluid in the initial diagnosis of glioma patients. Methods We collected the tumor tissues, preoperative blood plasma and cerebrospinal fluid from 283 patients with glioma admitted by neurosurgery. Contused brain tissues of 10 patients with craniocerebral trauma, and the corresponding blood plasma and cerebrospinal fluid were collected for the negative control. Methylation status of MGMT promoter was determined by methylationspecific PCR(MSP). The methylation rate of MGMT promoter was compared among tumor tissues, preoperative blood plasma and cerebrospinal fluid. Results The methylation rates of glioma tissues, the corresponding peripheral blood and cerebrospinal fluid promoters were 67.14%, 44.87% and 66.08%, respectively, and 0 in the negative control group. The positive rates of MGMT promoter methylation in different grades of gliomas were 68.13% (WHO Ⅱ), 65.69% (WHO Ⅲ) and 67.78% (WHO Ⅳ), respectively (P>0.05). In the glioma tissues with positive MGMT promoter methylation, the sensitivity of MGMT promoter methylation in cerebrospinal fluid was 79.66% (141/177), higher than that in blood plasma (58.82%(110/187)) (P<0.05). Conclusion The methylation rates of MGMT promoter in tumor tissues, cerebrospinal fluid and peripheral blood are independent of tumor grade. Compared with peripheral blood, the methylation of MGMT promoter in cerebrospinal fluid is more specific and sensitive.
Keywords:Humoral DNA  Methylation  Early diagnosis of glioma  MGMT gene promoter  Cerebrospinal fluid  R730  264
点击此处可从《肿瘤防治研究》浏览原始摘要信息
点击此处可从《肿瘤防治研究》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号